product name Lisinopril
Description: Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor used in treatment of hypertension, congestive heart failure, and heart attacks, and also in preventing renal and retinal complications of diabetes. Lisinopril significantly reduces left ventricular (LV) end-diastolic pressure (EDP), pulmonary capillary wedge pressure (PCWP) and end-diastolic stress, addition of atenolol to Lisinopril further reduces EDP and PCWP. Lisinopril is a structural homologue of enalaprilat, differing only in the second amino acid side chain.
References: J Am Coll Cardiol. 2002 Jul 3;40(1):149-54; Biochim Biophys Acta. 1995 May 24;1236(1):31-8.
Formula
CAS No.
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO:
Water: <1 mg/mL
Ethanol:
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: Lisinopril significantly reduces left ventricular (LV) end-diastolic pressure (EDP), pulmonary capillary wedge pressure (PCWP) and end-diastolic stress, addition of atenolol to Lisinopril further reduces EDP and PCWP. Lisinopril is a structural homologue of enalaprilat, differing only in the second amino acid side chain. Lisinopril inhibits Angiotensin-converting enzyme (ACE) in vitro, as well as after parenteral and oral administration to humans; its oral bioavailability is only 25-29%, but it has a longer duration of action than enalapril. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Lisinopril treated SHR rats has significantly raised total cholesterol levels compared to untreated spontaneously hypertensive rats (SHR) rats (+27%), but not compared to lisinopril treated Wistar Kyoto rats (WKY) rats. Lisinopril is a long-acting angiotensin-converting enzyme inhibitor which blocks the renin-angiotensin system (RAS) and reduces systemic blood pressure in rats. Lisinopril reduces the hydroxyproline level and inhibits accumulation of collagens in the pulmonary tissue of the treatment group (paraquat + lisinopril) and per-treatment group (lisinopril + paraquat) in rats. Lisinopril results in preserved ultrafiltration volume (UF), glucose reabsorption (D 1 /D 0 glucose) and peritoneal thickness in rats. Lisinopril (0.2 mg/kg twice a day for 10 days) protects the cell membrane integrity and lessens free radical-induced oxidant stress in guinea pig hearts. |
| Animal model | |
| Formulation & Dosage | |
| References | J Am Coll Cardiol. 2002 Jul 3;40(1):149-54; Biochim Biophys Acta. 1995 May 24;1236(1):31-8; Clin Chim Acta. 2000 Sep;299(1-2):1-10. |
